ClinicalTrials.gg
Active, not recruitingNCT07849478Updated Sep 30, 2026

Two-year Clinical Performance of Ion-releasing and Conventional Bulk-fill Resin Composite Restorative Systems.

An interventional study of self-cure ion-releasing bulk-fill resin composite and ion-releasing bulk-fill resin composite in Class I Dental Caries, sponsored by Mansoura University. Active, not recruiting at 1 site in Egypt. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Mansoura University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled May 2025, registered Sep 2026).
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Dental Caries by Mansoura University — 5 open to participants now, 12 under way, none of them phase 3. Dental Caries · Mansoura University.

Enrollment
15th of 19
30 · median 40
Started
2025
with 5 others
No phase
19 of 19
5 open now
Primary completion
2027-05
later than 9 of 11 live
Registered
18th of 19
by date

Among the 19 studies in Dental Caries by Mansoura University, this one is the 15th largest by enrollment, is one of 6 that started in 2025, is one of 19 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 18th registered.

Dental Caries

1,176 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

Browse Dental Caries studies →

Open to participants now

5 of the 19 studies in Dental Caries by Mansoura University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.

This study: 20 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Dental Caries by Mansoura University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if ion-releasing composite works to induce remineralization in caries-affected dentin in adults.

This study was designed to test the null hypothesis that there was no significant differences in: The two-year clinical performance of ion-releasing and conventional bulk-fill resin composite restorative systems.

Participants:

  • received three different restorative systems
  • Visit the clinic once every 6 months for checkups and tests
03

Conditions studied

  • Class I Dental Caries

Browse trials for

Keywords

  • ion-releasing, dentin remineralization, class I
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Eligibility Criteria

Inclusion criteria

Inclusion Criteria:

Male or female gender. Only cooperative patients are approved to participate in the trial Medically free adult patients. The age range of the patients is 20- 40 years who have at least three Class I carious lesions.

Patients with normal occluusion

Exclusion criteria

Exclusion Criteria:

Allergic history concerning methacrylates Pregnancy. Heavy smoking; xerostomia. Lack of compliance. Patients with disabilities. Patients who have systemic diseases or severe medically compromised patients. Patients with severe bruxism, clenching, or temporomandibular joint disorders.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Group 1: self-cure ion-releasing bulk-fill resin composite

    Test arm

    Device: self-cure ion-releasing bulk-fill resin composite

  • Experimental
    Group 2: ion-releasing bulk-fill resin composite

    Test arm

    Device: ion-releasing bulk-fill resin composite

  • Experimental
    Group 3: conventional bulk-fill resin composite

    Control arm

    Device: conventional bulk-fill resin composite

Interventions

  • Deviceself-cure ion-releasing bulk-fill resin composite

    class I cavity preparation and restoration with self-cure ion-releasing bulk-fill resin composite

  • Deviceion-releasing bulk-fill resin composite

    class I cavity preparation and restoration with ion-releasing bulk-fill resin composite

  • Deviceconventional bulk-fill resin composite

    class I cavity preparation and restoration with conventional bulk-fill resin composite

06

What researchers measure

Primary outcomes

  1. Clinical evaluation scores of Class I restorations according to the revised 2023 FDI criteria

    FDI criteria score-Functional (F1 Fracture/Retention; F2 marginal adaptation; F5 Occlusion and wear), biological (B1 caries at restoration margin; B2 dental hard tissue defects at restoration margin; B3 Postoperative hyper-sensitivity), Aesthetic properties (A2 Marginal staining), According to the revised 2023 FDI criteria for, 1. Functional properties Restorations will be evaluated for F1 (fracture/retention), F2 (marginal adaptation), and F5 (Occlusion and wear) 2. Biological properties Restoration assessment of B1 (caries at restoration margin), B2 (dental hard tissue defects at restoration margin), and B3 Postoperative hyper-sensitivity) 3. Aesthetic properties Restorations will be evaluated for A2 (marginal staining) * Mean (SD) scores and the proportion of clinically acceptable restorations (scores 1-3) versus unacceptable restorations (scores 4-5) will be reported. Lower scores indicate better clinical performance. * Unit of Measure: FDI score

    Time frame: one week, 6, 12, and 24 months

Secondary outcomes

  1. Clinical evaluation scores of Class I restorations according to the revised 2023 FDI criteria

    FDI criteria score-Aesthetic properties (A1) Surface luster and surface texture, Miscellaneous properties (M1) Patient's view, according to the revised 2023 FDI criteria for, 1. Aesthetic properties: (A1) Surface luster and surface texture 2. Miscellaneous properties: (M1) Patient's view * Mean (SD) scores and the proportion of clinically acceptable restorations (scores 1-3) versus unacceptable restorations (scores 4-5) will be reported. Lower scores indicate better clinical performance. * Unit of Measure: FDI score

    Time frame: one week, 6, 12, and 24 months

07

Study locations

1 site
08

References and documents

Publications

  • Raghip AGM, Comisi JC, Hamama HH, Mahmoud SH. Two-year randomized clinical trial to evaluate the performance of posterior bulk-fill resin composite with ionic releasing restorative material. J Dent. 2025 Sep;160:105912. doi: 10.1016/j.jdent.2025.105912. Epub 2025 Jun 13. PubMed 40518039 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 470 non-industry interventional studies with no phase under Dental Caries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 24 months is above that.

Counting every sponsor, half of 503 studies reached it within 15 months; a quarter within 7 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2026
First posted
Sep 30, 2026
StartActual
May 29, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849478
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
May 29, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion